BR96 sFv-PE40 immunotoxin: Nonclinical safety assessment

Toxicologic Pathology

Volumn 27, Issue 1, 1999, Pages 87-94

  Haggerty, Helen G ^a   Warner, W A ^a   Comereski, C R ^a   Peden, W M ^a   Mezza, L E ^a   Damle, B D ^b   Siegall, C B ^c   Davidson, T J ^a  

^a BRISTOL MYERS SQUIBB COMPANY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c SEATTLE GENETICS INC   (United States)

Author keywords

BR96 SFv PE40; Immunotoxin; Safety

Indexed keywords

HYBRID PROTEIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BR 96; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; CONFERENCE PAPER; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG ANTIGENICITY; DRUG CLEARANCE; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HYDROTHORAX; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MALE; NONHUMAN; PANCREAS INJURY; PRIORITY JOURNAL; RAT; RISK ASSESSMENT;

ANIMALIA; CANIS FAMILIARIS; PSEUDOMONAS; PSEUDOMONAS EXOTOXIN; RODENTIA;

EID: 0033012743     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339902700116     Document Type: Conference Paper

References (17)

1. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, and Vitteta ES (1993). A phase I study of an anti-CD22 deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 9: 2624-2633.
2. Friedman PN, McAndrew SJ, Gawlak SL, Chace D, Trail PA, and Siegall CB (1993). BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. Cancer Res. 53: 334.
3. Ghetie V and Vitetta E (1994). Immunotoxins in the therapy of cancer: From bench to clinic. Pharmacol. Ther. 63: 209-234.
4. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blättler WA, Taylor JA, and Nadler LM (1992). Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion. Blood 79: 576-585.
5. Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blättler WA, Epstein CL, and Nadler LM (1993). Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusions in patients with B-cell neoplasms. J. Clin. Oncol. 11: 726-737.
6. y-related cell surface antigens. Cancer Res. 50: 2183.
7. Keller ET (1990). High serum trypsin-like immunoreactivity secondary to pancreatitis in a dog with exocrine pancreatic insufficiency. J. Am. Vet. Med. Assoc. 196: 623-626.
8. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 79: 2547-2554.
9. Levitt MD and Eckfeldt JH (1993). Diagnosis of acute pancreatitis. In: The Pancreas: Biology, Pathobiology, and Disease, VLW Go, E Lebenthal, EP Di Magno, HA Reber, JD Gardner and GA Scheele (eds). Raven Press, New York, pp. 613-635.
10. Siegall CB, Chace D, Mixan B, Garrigues U, Wan H, Paul L, Hellström I, and Hellström KE (1994). In vitro and in vivo characterization of BR96 sFv-PE40, single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats. J. Immunol. 152: 2377.
11. Siegall CB, Haggerty HG, Warner GL, Chace D, Mixan B, Linsley P, and Davidson TJ (1997). Prevention of immunotoxin-mediated immunogenicity by blockade of CD28-B7 mediated co-stimulation using CTLA4-Ig. J. Immunol. 159: 5168-5173.
12. Siegall CB, Liggitt D, Chace D, Mixan B, Sugar J, Davidson T, and Stains M (1997). Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin. Cancer Res. 3: 339-345.
13. Siegall CB, Liggitt D, Chace D, Tepper MA, and Fell HP (1994). Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc. Natl. Acad. Sci. USA 91: 9514-9518.
14. Spitler LE, del Rio M, Khentigan A, Wedel NI, Brophy NA, Miller LL, Harkonen WS, Rosendorf LL, Lee HM, Misschak RP, Kawahata RT, Stoudemire JB, Fradkin LB, Bautista EE, and Scannon PJ (1987). Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res. 47: 1717-1723.
15. Vitteta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr JW, and Thorpe PE (1991). Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51: 4052-4058.
16. Williams DA (1987). New tests of pancreatic and small intestinal function. Compend. Cont. Educ. Pract. Vet. 9: 1167-1175.
17. Williams DA and Batt RM (1983). Diagnosis of canine exocrine pancreatic insufficiency by the assay of serum trypsin-like immunoreactivity. J. Small Anim. Pract. 24: 583-588.